Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867711/
Multiple myeloma (MM) is a malignant proliferative disease of plasma cells, which leads to suppressed hematopoietic and osteolytic diseases. Despite the use of traditional chemotherapy, hematopoietic stem cell transplantation (HSCT)...
-
Mark Fesler4yrThis paper is a very nice review of chimeric antigen T cell therapy for multiple myeloma, and this therapy will likely become a major advance in the treatment of this Show More
Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862995/
Autologous stem cell transplantation (ASCT) is one of the standard treatments of choice for eligible multiple myeloma (MM) patients. Herein, we aimed to analyze MM patients at our center and...
-
Mark Fesler4yrWould caution drawing conclusions on this retrospective study as patients who received a double autoSCT may have had inferior survival simply related to biologically worse disease
Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance
Source : https://link.springer.com/article/10.1007/s12254-021-00689-2
AL amyloidosis (AL) and monoclonal gammopathy of renal significance (MGRS) are both paraprotein-associated diseases. Both entities are based on a monoclonal paraprotein produced by a clonal plasma-cell population like in...
Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review.
Source : https://europepmc.org/article/med/33518613
Few reports have so far described central nervous system (CNS) involvement in multiple myeloma (MM), which shows a poor prognosis owing to its resistance to several treatments. We herein describe...
HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
Source : https://www.mdpi.com/1422-0067/22/3/1341/htm
Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance...